NCT04808037: Phase 1/2: Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM (BelaRd)
What is the best diet for myeloma patients to build a strong immune system? IMF
Miami Myeloma MRD 2021 Virtual Meeting October 13, 2021
63RD ASH ANNUAL MEETING AND EXPOSITION -Atlanta, GA December 11-14, 2021
NCCN Patient Webinar: Multiple Myeloma
Multiple Myeloma Research Foundation - MMRF - Learn Your Labs | High Impact Topic (HIT)
NCT05027594: Phase 1: Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Myeloma
NCT04937777: EMN 23 - Study on the Management & Outcome of Systemic AL Amyloidosis in Europe
NIH: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3
BMT CTN Immune and Cellular Therapy in Multiple Myeloma Workshop Friday Jan 7th, 2022-10 am - 1 pm
NCT05028348: Phase 3: EMN 29 - Selinexor, Pom, Dex (SPd) Vs Elotuzumab, Pom, Dex in RRMM Myeloma
FDA Approved for RRMM:Daratumumab and Hyaluronidase-fihj(Darzalex Faspro) + Kyprolis & Dexamethasone
NCT05020236: Phase 3-MagnetisMM-5: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex
NCT05060627: Phase 1/2: Belantamab Mafodotin + Kd RRMM Multiple Myeloma, Refractory to Lenalidomide
NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab RRMM
Patient Symposium - MCRT Webcast Myeloma Crowd Round Table, 06/26/2021
NCT05123131: Phase 2: Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD)
Abecma: CART Cell Therapy -FDA Approves First Cell-Based Gene Therapy for Adult Patients with RRMM